Nuclear Decloaker is a Tris buffer heat retrieval solution, pH 9.5. It is specially designed for nuclear antigens including ER, PR, Ki-67, p53, cyclin D1, TdT and TTF-1. Other antibodies that show improved staining include ALK1, ALKc, bcl-2, CA125, CD3 (M), CD15, CD30, CD31, CD79a, MART-1, Tyrosinase and Villin. Nuclear Decloaker can be used with […]
EDTA Decloaker is a heat retrieval solution, pH 8.4-8.7. Recommended for use with antibodies with low antigen expression (cyclin D1, CD1a, CD3, CD4, CD8, CD23, bcl-6, CD61, CD79a and TdT). EDTA Decloaker is a potent agent for epitope retrieval and tissues may be 5-10 times more sensitive to immunohistochemical staining. EDTA Decloaker can be used […]
NKX is a prostate-specific tumor suppressor gene and loss of a single allele may predispose to prostate carcinogenesis (1). Studies have shown that the onset of MYC overexpression and the subsequent development of prostatic intraepithelial neoplasia coincide with this reduction in NKX (2). Over-expression of MYC has been reported as an early oncogenic event driving […]
LAG-3 (Lymphocyte Activation Gene 3) is a surface receptor expressed on activated T cells, an exhaustion marker with immunosuppressive activity (1). Major histocompatibility complex class II (MHC-II) is a ligand for LAG-3; additional ligands (e.g., LSECtin and galectin-3) have also been identified (1,2). Regulatory T cells (Tregs) expressing LAG-3 have enhanced suppressive activity, whereas cytotoxic […]
Immunoglobulin G (IgG) is an antibody isotype secreted by plasma cells and composed of four peptide chains – two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers (1). In humans, IgG consists of four subclasses that differ only marginally in their amino acid composition (1). Representing approximately […]
IGH rearrangements including translocations and fusions involving a variety of other genes is a common event. Numerous studies have shown that these rearrangements, with, for example MYC, MAF, CCND1 and MALT1 to be implicated in numerous hematological tumors including lymphomas, leukemia’s and multiple myeloma1,2,3,4. FOR DISTRIBUTION OUTSIDE THE UNITED STATES ONLY
IGH rearrangements including translocations and fusions involving a variety of other genes is a common event. Numerous studies have shown that these rearrangements, with, for example MYC, MAF, CCND1 and MALT1 to be implicated in numerous hematological tumors including lymphomas, leukemia’s and multiple myeloma1,2,3,4. FOR DISTRIBUTION OUTSIDE THE UNITED STATES ONLY
CD4 is expressed in a T-cell subset (helper/inducer) and is found in approximately 80% of thymocytes and in 45% of peripheral blood lymphocytes. CD4 is expressed in the majority of T-cell lymphomas including mycosis fungoides, a common form of cutaneous T-cell lymphoma (1). CD8 has been shown to be an important marker in the analysis […]
The CD8 antibody reacts with the 32 kDa CD8 protein. CD8 stains cells with cytotoxic activity, including cortical thymocytes, cytotoxic/suppressor T-cells and a subset of natural killer cells. CD4 and CD8 positive and negative staining are indicative of T-cell neoplasms (1-2). CD4 and CD8 may also be used to differentiate between mycosis fungoides and cutaneous […]
The Biocare CD33 antibody detects CD33 (Siglec-3), a 67 kDa glycosylated transmembrane receptor expressed on myeloid-specific cells.15, 16 Historically, CD33 was primarily used for flow cytometry; more recently, a paraffin embedded tissue–compatible CD33 antibody has been developed. CD33 is useful for phenotyping acute myelogenous leukemias, with immunohistochemical (IHC) analysis providing results equivalent to flow cytometry.15, […]
